

DETD . . . carboxymethyl cellulose, Avicel®RC-591, tragacanth and sodium alginate; typical wetting agents include lecithin and polysorbate 80; and typical preservatives include methyl paraben and sodium benzoate. Peroral liquid compositions may also contain one or more components such as sweeteners, flavoring agents and colorants. . . .

DETD Beclomethasone, preferably at a dosage range of from about 84 to about 336 ug; Fluticasone, preferably at a dosage range of from about 50 to about 400 ug; Budesonide, preferably at a dosage range of. . .

L22 ANSWER 21 OF 21 USPATFULL

Full-text

ACCESSION NUMBER: 96:68029 USPATFULL

TITLE: 5-(2-imidazolinyllamino)benzimidazole compounds useful as alpha-2 andrenoceptor agonists

INVENTOR(S): Cupps, Thomas L., Oxford, OH, United States
Bogdan, Sophie E., Maineville, OH, United States

PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5541210		19960730
APPLICATION INFO.:	US 1995-496706		19950629 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-349558, filed on 8 Dec 1994, now patented, Pat. No. US 5478858 which is a continuation-in-part of Ser. No. US 1993-169868, filed on 17 Dec 1993, now abandoned		
DOCUMENT TYPE:	Utility		
PRIMARY EXAMINER:	Jordan, Kimberly		
LEGAL REPRESENTATIVE:	Hake, Richard A., Clark, Karen F., Graff, IV, Milton B.		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1290		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The subject invention involves compounds having the following structure:
##STRI## wherein: (a) R is unsubstituted C1 -C3 alkanyl or alkenyl;

(b) R' is selected from hydrogen; unsubstituted C1 -C3 alkanyl or alkenyl; unsubstituted C1 -C3 alkylthio or alkoxy; hydroxy; thiol; cyano; and halo; and

(c) R' is selected from hydrogen, methyl, ethyl and i-propyl.

The subject invention also involves pharmaceutical compositions containing such novel compounds, compositions thereof and the use of such compounds for preventing or treating respiratory, ocular and/or gastrointestinal disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . cellulose, Avicel® RC-591, tragacanth and sodium alginate; typical wetting agents include lecithin and polysorbate 80; and typical preservatives include methyl paraben and sodium benzoate. Peroral liquid compositions may also contain one or more components such as sweeteners, flavoring agents and colorants. . . .

DETD Beclomethasone, preferably at a dosage range of from about 84 to about 336 ug; Fluticasone, preferably at a dosage range of from about 50 to about 400 ug; Budesonide, preferably at a dosage range of. . .

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	41.30	135.23

STN INTERNATIONAL LOGOFF AT 23:06:05 ON 10 JUL 2001

FILE 'HOME' ENTERED AT 22:36:21 ON 10 JUL 2001

=> fil reg

=> s fluticasone/cn

L1 1 FLUTICASONE/CN

=> s cetostearyl alcohol/cn

L2 1 CETOSTEARYL ALCOHOL/CN

=> s isopropyl myristate/cn

L3 1 ISOPROPYL MYRISTATE/CN

=> s dimethicone/cn

L4 1 DIMETHICONE/CN

=> s cetomacrogol/cn

L5 1 CETOMACROGOL/CN

=> s propylene glycol/cn

L6 1 PROPYLENE GLYCOL/CN

=> s imidurea

0 IMIDUREA

L7 0 IMIDUREA

=> s methyl paraben/cn

L8 0 METHYL PARABEN/CN

=> s imidurea/cn

L9 0 IMIDUREA/CN

=> s paraben

18 PARABEN

1 PARABENS

L10 18 PARABEN

(PARABEN OR PARABENS)

=> s propyl paraben/cn

L11 0 PROPYL PARABEN/CN

=> d his

(FILE 'HOME' ENTERED AT 22:36:21 ON 10 JUL 2001)

FILE 'REGISTRY' ENTERED AT 22:37:20 ON 10 JUL 2001

L1 1 S FLUTICASONE/CN

L2 1 S CETOSTEARYL ALCOHOL/CN

L3 1 S ISOPROPYL MYRISTATE/CN

L4 1 S DIMETHICONE/CN

L5 1 S CETOMACROGOL/CN

L6 1 S PROPYLENE GLYCOL/CN

L7 0 S IMIDUREA

L8 0 S METHYL PARABEN/CN

L9 0 S IMIDUREA/CN

L10 18 S PARABEN

L11 0 S PROPYL PARABEN/CN

=> fil caplus

=> s (l1 or fluticasone) and (l2 or cetostearyl) and (l3 or isopropyl myristate) and (l4 or dimethicone) and (l5 or cetomacrogol)

96 L1

488 FLUTICASONE

109 L2

594 CETOSTEARYL

1900 L3

39545 ISOPROPYL

4 ISOPROPYLS

39546 ISOPROPYL

(ISOPROPYL OR ISOPROPYLS)

20368 MYRISTATE

68 MYRISTATES

20406 MYRISTATE

(MYRISTATE OR MYRISTATES)

1532 ISOPROPYL MYRISTATE
 (ISOPROPYL(W)MYRISTATE)
 579 L4
 1237 DIMETHICONE
 12 DIMETHICONES
 1239 DIMETHICONE
 (DIMETHICONE OR DIMETHICONES)
 60 L5
 198 CETOMACROGOL
 1 CETOMACROGOLS
 198 CETOMACROGOL
 (CETOMACROGOL OR CETOMACROGOLS)
 L12 1 (L1 OR FLUTICASONE) AND (L2 OR CETOSTEARYL) AND (L3 OR ISOPROPYL
 MYRISTATE) AND (L4 OR DIMETHICONE) AND (L5 OR CETOMACROGOL)

=> d

L12 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2001 ACS

Full-text

AN 2000:290840 CAPLUS
 DN 132:313720
 TI Fluticasone lotion having improved vasoconstrictor activity
 IN Dow, Gordon J.; Johnson, Keith Arthur; Kelly, Frances Furr; Lathrop,
 Robert William; Rajagopalan, Rukmini
 PA Glaxo Group Limited, UK
 SO PCT Int. Appl., 28 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000024401	A1	20000504	WO 1999-GB3472	19991020
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9963524	A1	20000515	AU 1999-63524	19991020
PRAI	GB 1998-23036	A	19981022		
	WO 1999-GB3472	W	19991020		

RE.CNT 4

RE

- (1) Aktiebolaget, D; EP 0042827 A 1981 CAPLUS
- (2) Bleeheh, S; BRITISH JOURNAL OF DERMATOLOGY 1995, V133(4), P592 CAPLUS
- (3) Glaxo Group Ltd; WO 9214472 A 1992 CAPLUS
- (4) Spencer, C; BIODRUGS 1997, V7(4), P318 CAPLUS

=> index bioscience

INDEX 'ADISALERTS, ADISINSIGHT, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, ...' ENTERED AT 22:43:38 ON 10 JUL 2001

59 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
 search error messages that display as 0* with SET DETAIL OFF.

=> s (l1 or fluticasone) and (l2 or cetostearyl) and (l3 or isopropyl myristate) and (l4 or dimethicone)
 and (l5 or cetomacrogol) and (l8 or paraben)

0* FILE ADISALERTS
 0* FILE AQUASCI
 0* FILE BIOCOMMERCE
 0* FILE CABA
 0* FILE CAPLUS
 0* FILE CEABA-VTB

16 FILES SEARCHED...

0* FILE CONFSCI

0* FILE CROPB
0* FILE CROPU
0* FILE DDFB
0* FILE DDFU
22 FILES SEARCHED...
0* FILE DGENE
0* FILE DRUGB
0* FILE DRUGU
0* FILE EMBAL
0* FILE ESBIODASE
0* FILE FOMAD
0* FILE FOREGE
0* FILE FROSTI

36 FILES SEARCHED...
0* FILE GENBANK
0* FILE HEALSAFE
0* FILE IFIPAT
0* FILE KOSMET
0* FILE LIFESCI
0* FILE MEDICONF
0* FILE NTIS
0* FILE OCEAN
0* FILE PASCAL
0* FILE PHIC
0* FILE PHIN
0* FILE SCISEARCH

54 FILES SEARCHED...
0* FILE USPATFULL

0 FILES HAVE ONE OR MORE ANSWERS, 59 FILES SEARCHED IN STNINDEX

L13 QUE (L1 OR FLUTICASONE) AND (L2 OR CETOSTEARYL) AND (L3 OR ISOPROPYL MYRIS
TATE) AND (L4 OR DIMETHICONE) AND (L5 OR CETOMACROGOL) AND (L8 OR PARA
BEN)

=> s (l1 or fluticasone) and (l4 or dimethicone)

0* FILE ADISALERTS
0* FILE AQUASCI
0* FILE BIOCOMMERCE
0* FILE CABA
1* FILE CAPLUS
0* FILE CEABA-VTB
0* FILE CONFSCI
0* FILE CROPB
0* FILE CROPU
0* FILE DDFB
0* FILE DDFU
0* FILE DGENE
0* FILE DRUGB
0* FILE DRUGU

29 FILES SEARCHED...
0* FILE EMBAL
0* FILE ESBIODASE
0* FILE FOMAD
0* FILE FOREGE
0* FILE FROSTI
0* FILE GENBANK
0* FILE HEALSAFE
0* FILE IFIPAT
0* FILE KOSMET
0* FILE LIFESCI
0* FILE MEDICONF
0* FILE NTIS
0* FILE OCEAN
0* FILE PASCAL
0* FILE PHIC
0* FILE PHIN
0* FILE SCISEARCH
1 FILE TOXLIT
0* FILE USPATFULL
1 FILE WPIDS
1 FILE WPINDEX

4 FILES HAVE ONE OR MORE ANSWERS, 59 FILES SEARCHED IN STNINDEX

L14 QUE (L1 OR FLUTICASONE) AND (L4 OR DIMETHICONE)

=> s steroid and (dimethicone or l4)

0* FILE ADISALERTS
0* FILE AQUASCI
0* FILE BIOCOMMERCE
2 FILE BIOSIS
0* FILE CABA
17* FILE CAPLUS
0* FILE CEABA-VTB
0* FILE CONFSCI
0* FILE CROPB
0* FILE CROPU

20 FILES SEARCHED...

0* FILE DDFB
1* FILE DDFU
0* FILE DGENE
0* FILE DRUGB
4* FILE DRUGU
0* FILE EMBAL
2 FILE EMBASE
0* FILE ESBIODASE
0* FILE FOMAD
0* FILE FOREGE
0* FILE FROSTI
0* FILE GENBANK
0* FILE HEALSAFE
3* FILE IFIPAT
0* FILE KOSMET
0* FILE LIFESCI

42 FILES SEARCHED...

0* FILE MEDICONF
2 FILE MEDLINE
0* FILE NTIS
0* FILE OCEAN
1* FILE PASCAL
0* FILE PHIC
0* FILE PHIN
6 FILE PROMT
1* FILE SCISEARCH
2 FILE TOXLINE
1 FILE TOXLIT
134* FILE USPATFULL
6 FILE WPIDS
6 FILE WPINDEX

15 FILES HAVE ONE OR MORE ANSWERS, 59 FILES SEARCHED IN STNINDEX

L15 QUE STEROID AND (DIMETHICONE OR L4)

=> d rank

F1 134* USPATFULL
F2 17* CAPLUS
F3 6 PROMT
F4 6 WPIDS
F5 6 WPINDEX
F6 4* DRUGU
F7 3* IFIPAT
F8 2 BIOSIS
F9 2 EMBASE
F10 2 MEDLINE
F11 2 TOXLINE
F12 1 TOXLIT
F13 1* DDFU
F14 1* PASCAL
F15 1* SCISEARCH

=> s steroid and (12 or cetostearyl) and (13 or isopropyl myristate) and (14 or dimethicone) and (15 or cetomacrogol)

0* FILE ADISALERTS
0* FILE AQUASCI
0* FILE BIOCOMMERCE
0* FILE CABA
0* FILE CAPLUS

0* FILE CEABA-VTB
 0* FILE CONFSCI
 0* FILE CROPB
 0* FILE CROPU
 0* FILE DDFB

21 FILES SEARCHED...

0* FILE DDFU
 0* FILE DGENE
 0* FILE DRUGB
 1* FILE DRUGU
 0* FILE EMBAL
 0* FILE ESBIODASE
 0* FILE FOMAD
 0* FILE FOREGE
 0* FILE FROSTI
 0* FILE GENBANK
 0* FILE HEALSAFE
 0* FILE IFIPAT
 0* FILE KOSMET
 0* FILE LIFESCI
 0* FILE MEDICONF

45 FILES SEARCHED...

0* FILE NTIS
 0* FILE OCEAN
 0* FILE PASCAL
 0* FILE PHIC
 0* FILE PHIN
 0* FILE SCISEARCH
 0* FILE USPATFULL

1 FILES HAVE ONE OR MORE ANSWERS, 59 FILES SEARCHED IN STNINDEX

L16 QUE STEROID AND (L2 OR CETOSTEARYL) AND (L3 OR ISOPROPYL MYRISTATE) AND (L4 OR DIMETHICONE) AND (L5 OR CETOMACROGOL)

=> d rank

F1 1* DRUGU

=> fil f1

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.61	61.82

FILE 'DRUGU' ENTERED AT 22:50:05 ON 10 JUL 2001
 COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE LAST UPDATED: 06 JUL 2001 <20010706/UP>
 >>> DERWENT DRUG FILE (SUBSCRIBER) <<<

>>> SDI'S MAY BE RUN WEEKLY OR MONTHLY AS OF JUNE 2001. <<<
 >>> (WEEKLY IS THE DEFAULT). FOR PRICING INFORMATION <<<
 >>> SEE HELP COST <<<

>>> FILE COVERS 1983 TO DATE <<<
 >>> THESAURUS AVAILABLE IN /CT <<<

=> s l16

13460 STEROID
 11998 STEROIDS
 21914 STEROID
 (STEROID OR STEROIDS)
 27 L2
 160 CETOSTEARYL
 90 L3
 2385 ISOPROPYL
 1 ISOPROPYLS
 2385 ISOPROPYL
 (ISOPROPYL OR ISOPROPYLS)
 2634 MYRISTATE
 1 MYRISTATES
 2634 MYRISTATE
 (MYRISTATE OR MYRISTATES)
 505 ISOPROPYL MYRISTATE

(ISOPROPYL(W)MYRISTATE)
4 L4
98 DIMETHICONE
3 DIMETHICONES
100 DIMETHICONE
(DIMETHICONE OR DIMETHICONES)
15 L5
88 CETOMACROGOL

L17 1 STEROID AND (L2 OR CETOSTEARYL) AND (L3 OR ISOPROPYL MYRISTATE)
AND (L4 OR DIMETHICONE) AND (L5 OR CETOMACROGOL)

=> d

L17 ANSWER 1 OF 1 DRUGU COPYRIGHT 2001 DERWENT INFORMATION LTD

Full-text

AN 1998-13363 DRUGU T E S
TI The role of clobetasol propionate emollient 0.05 % in the treatment of patients with dry, scaly, corticosteroid-responsive dermatoses.
AU Gordon M L
LO New York, N.Y., USA
SO Clin.Ther. (20, No. 1, 26-39, 1998) 1 Fig. 2 Tab. 34 Ref.
CODEN: CLTHDG ISSN: 0149-2918
AV Department of Dermatology, Mount Sinai Medical Center, One Gustave L. Levy Place, New York, NY 10029-6574, U.S.A.
LA English
DT Journal
FA AB; LA; CT
FS Literature

=> d abs kwic

L17 ANSWER 1 OF 1 DRUGU COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 1998-13363 DRUGU T E S

AB The role of clobetasol propionate emollient 0.05 % in the treatment of patients with dry, scaly, corticosteroid-responsive dermatoses is reviewed. Tolerability and safety are discussed. Recent studies in the use of clobetasol emollient suggest that it is well tolerated and efficacious in courses of up to 4 wk for the treatment of patients with plaque-type psoriasis or atopic dermatitis. Improvements in signs and symptoms may continue for 2 wk after discontinuation of treatment.

ABEX The role of clobetasol propionate emollient 0.05 % in the treatment of patients with dry, scaly, corticosteroid-responsive dermatoses is reviewed. Tolerability and safety are discussed. An emollient added to a steroid, although not itself an active ingredient, can help restore the normal moisturizing process of the skin; this may be particularly important in soothing the discomfort of the dry skin conditions often encountered in moderate-to-severe dermatoses. In addition, the degree of epidermal hydration can affect the penetration of steroids into the skin. Therefore, successful outcomes in the treatment of patients with corticosteroid-responsive dermatoses may involve more than use of an effective topical steroid. Ingredients in clobetasol propionate cream include cetostearyl alcohol, cetomacrogol 1000, isopropyl myristate, propylene glycol, dimethicone 360, citric acid, sodium citrate and imidurea. Recent studies in the use of clobetasol emollient suggest that it is well tolerated and efficacious in courses of up to 4 wk for the treatment of patients with plaque-type psoriasis or atopic dermatitis. Improvements in signs and symptoms may continue for 2 wk after discontinuation of treatment. (LAJ)

ABEX. . . treatment of patients with dry, scaly, corticosteroid-responsive dermatoses is reviewed. Tolerability and safety are discussed. An emollient added to a steroid, although not itself an active ingredient, can help restore the normal moisturizing process of the skin; this may be particularly. . . dry skin conditions often encountered in moderate-to-severe dermatoses. In addition, the degree of epidermal hydration can affect the penetration of steroids into the skin. Therefore, successful outcomes in the treatment of patients with corticosteroid-responsive dermatoses may involve more than use of an effective topical steroid. Ingredients in clobetasol propionate cream include cetostearyl alcohol, cetomacrogol 1000, isopropyl myristate, propylene glycol, dimethicone 360, citric acid, sodium citrate and imidurea. Recent studies in the use of clobetasol emollient suggest that it is well. . .

=> index bioscience
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
3.91	65.73

FULL ESTIMATED COST

INDEX 'ADISALERTS, ADISINSIGHT, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS,
BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT,
CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE,
DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, ...' ENTERED AT 22:52:23 ON 10 JUL 2001

59 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s (12 or cetostearyl) and (13 or isopropyl myristate) and (14 or dimethicone) and (15 or
cetomacrogol)

- 0* FILE ADISALERTS
- 0* FILE AQUASCI
- 0* FILE BIOCOMMERCE
- 0* FILE CABA
- 1* FILE CAPLUS
- 0* FILE CEABA-VTB
- 0* FILE CONFSCI
- 0* FILE CROPB
- 0* FILE CROPU
- 0* FILE DDFB
- 0* FILE DDFU
- 0* FILE DGENE
- 0* FILE DRUGB

26 FILES SEARCHED...

- 1* FILE DRUGU
- 0* FILE EMBAL
- 0* FILE ESBIODASE
- 0* FILE FOMAD
- 0* FILE FOREGE
- 0* FILE FROSTI
- 0* FILE GENBANK
- 0* FILE HEALSAFE
- 0* FILE IFIPAT
- 0* FILE KOSMET
- 0* FILE LIFESCI
- 0* FILE MEDICONF
- 0* FILE NTIS
- 0* FILE OCEAN
- 0* FILE PASCAL
- 0* FILE PHIC
- 0* FILE PHIN
- 0* FILE SCISEARCH

55 FILES SEARCHED...

- 4* FILE USPATFULL
- 1 FILE WPIDS
- 1 FILE WPINDEX

5 FILES HAVE ONE OR MORE ANSWERS, 59 FILES SEARCHED IN STNINDEX

L18 QUE (L2 OR CETOSTEARYL) AND (L3 OR ISOPROPYL MYRISTATE) AND (L4 OR DIMETHI
CONE) AND (L5 OR CETOMACROGOL)

=> d rank

F1	4*	USPATFULL
F2	1	WPIDS
F3	1	WPINDEX
F4	1*	CAPLUS
F5	1*	DRUGU

=> fil f1-4

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
1.02	66.75

FULL ESTIMATED COST

FILE 'USPATFULL' ENTERED AT 22:53:43 ON 10 JUL 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 22:53:43 ON 10 JUL 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'CAPLUS' ENTERED AT 22:53:43 ON 10 JUL 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

=> s 118

L19 6 L18

=> dup rem 119

PROCESSING COMPLETED FOR L19

L20 5 DUP REM L19 (1 DUPLICATE REMOVED)

=> d ibib abs kwic tot

L20 ANSWER 1 OF 5 USPATFULL

Full-text

ACCESSION NUMBER: 2001:67163 USPATFULL
TITLE: Hair styling agents and compositions containing
hydrophobic hair styling polymers
INVENTOR(S): Leet, Julia Elizabeth, Cincinnati, OH, United States
PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United
States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6228352	B1	20010508
APPLICATION INFO.:	US 1994-335422		19941107 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-156655, filed on 22 Nov 1993, now abandoned Continuation of Ser. No. US 1992-828848, filed on 31 Jan 1992, now abandoned Continuation of Ser. No. US 1991-712026, filed on 7 Jun 1991, now abandoned		
DOCUMENT TYPE:	Utility		
PRIMARY EXAMINER:	Page, Thurman K.		
ASSISTANT EXAMINER:	Ware, T.		
LEGAL REPRESENTATIVE:	Lewis, Leonard W., Winter, William J.		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1200		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Hair styling agents, and aqueous base hair care compositions containing
them, wherein the hair styling agent comprises a water-insoluble hair
styling polymer with a volatile, water-insoluble diluent. The
water-insoluble hair styling polymer consists essentially of hydrophobic
monomer units. These compositions are particularly useful for
application to the hair in the form of a rinse-off hair care composition
comprising the hair styling agent and an aqueous carrier providing a
gel-like rheology.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . Dodecyl Sulfate/Cetyl Alcohol", 28 J. of Colloid and Interface
Science 82-91 (1968); Barry, et al., "The Self-Bodying Action of
Alkyltrimethylammonium Bromides/Cetostearyl Alcohol Mixed Emulsifiers;
Influence of Quaternary Chain Length", 35 J. of Colloid and Interface
Science 689-708 (1971); and Barry, et al., "Rheology of Systems
Containing Cetomacrogol 1000--Cetostearyl Alcohol, I. Self Bodying
Action", 38 J. of Colloid and Interface Science 616-625 (1972).

DETD . . . et al., issued May 26, 1981; British Specification 1,532,585,
published Nov. 15, 1978; and Fukushima, et al., "The Effect of
Cetostearyl Alcohol in Cosmetic Emulsions", 98 Cosmetics & Toiletries
89-112 (1983). Fatty esters included among those useful herein are
disclosed in. . .

DETD . . . carbonate, ethyl palmitate, isooctyl palmitate, methyl
ricinoleate, butyl ricinoleate, diisooctyl sebacate, triisobutyl
phosphate, isodecyl pelargonate, ethyl valerate, isocetyl alcohol,
octododecanol, isopropyl myristate, isostearyl alcohol and methyl
alkyl silicones having C2 -C20 alkyl and from 1 to about 500
siloxane monomer units.

DETD . . . No. 4,265,878, Keil, issued May 5, 1981; and U.S. Pat. No.

4,421,769, Dixon, et al., issued Dec. 20, 1983. Such dimethicone copolyol materials are also disclosed, in hair compositions, in British Patent Application 2,066,659, Abe, published Jul. 15, 1981 (incorporated by reference herein) and Canadian Patent 727,588, Kuehns, issued Feb. 8, 1966 (incorporated by reference herein). Commercially available dimethicone polydimethylsiloxane copolyols which can be used herein, include Silwet Surface Active Copolymers (manufactured by the Union Carbide Corporation); and Dow.

L20 ANSWER 2 OF 5 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD

Full-text

DUPLICATE 1

ACCESSION NUMBER: 2000-350575 [30] WPIDS
 DOC. NO. CPI: C2000-106614
 TITLE: Topical lotion comprising fluticasone, fatty alcohol, skin conditioning agent, propylene glycol, mineral oil or paraffin, and water, useful for increasing vasoconstrictor potency and for the treatment of skin conditions e.g. dermatosis.
 DERWENT CLASS: B01 D21
 INVENTOR(S): DOW, G J; JOHNSON, K A; KELLY, F F; LATHROP, R W; RAJAGOPALAN, R
 PATENT ASSIGNEE(S): (GLAX) GLAXO GROUP LTD
 COUNTRY COUNT: 90
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000024401	A1	20000504	(200030)*	EN	28
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL					
OA PT SD SE SL SZ TZ UG ZW					
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES					
FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS					
LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL					
TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
AU 9963524	A	20000515	(200039)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000024401	A1	WO 1999-GB3472	19991020
AU 9963524	A	AU 1999-63524	19991020

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9963524	A Based on	WO 200024401

PRIORITY APPLN. INFO: GB 1998-23036 19981022

AN 2000-350575 [30] WPIDS

AB WO 200024401 A UPAB: 20000624

NOVELTY - A novel topical lotion comprises (wt.%):

- (a) fluticasone (I) (0.005 - 1.0) or its salt or ester;
- (b) a 14-20C alcohol (1.0 - 10);
- (c) at least one skin conditioning agent (1.0 - 5.0);
- (d) propylene glycol (5.0 - 15.0);
- (e) mineral oil or white soft paraffin (up to 10); and
- (f) water (q.s.),

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also provided for the preparation of the lotion comprising mixing the components at an elevated temperature and heating or allowing to cool

ACTIVITY - Dermatological; antiinflammatory; antipruritic; vasoconstrictor.

MECHANISM OF ACTION - Corticosteroid antagonist

USE - To increase the vasoconstrictor potency of (I) and its salts, and for treating a skin condition selected from corticosteroid-responsive dermatosis, atopic dermatitis, inflammation, eczema, erythema, papulation, scaling, erosion, oozing, crusting or pruritis (claimed).

ADVANTAGE - Lotion significantly improves organoleptic feel and spreadability of (I) over large area compared to cream containing (I). Improved vasoconstrictor activity compared to cream formulations. Systemically safe. Chemically and physically stable for at least 6 months at 40 deg. C (claimed).

Dwg.0/0

TECH.

- (I) (0.005 - 1.0) or its salt or ester, preferably fluticasone propionate (0.05);
(b) a 14-20C alcohol (3.0 - 7.0), preferably cetostearyl alcohol (5.0);
(c) at least one skin conditioning agent (0.5 - 3.0), preferably isopropyl myristate (1.0);
(d) at least 1 surfactant (0.25 - 2.0), preferably cetomacrogol (1.0);
(e) propylene glycol (7.0 - 12.0; preferably 10.0);
(f) mineral oil or white soft paraffin (up to 10.0);
(g) dimethicone (less than 5.0; preferably 1.0) and
(h) water (q.s.),
The lotion has a viscosity of 2000 - 17000 (preferably 3000. . .

L20 ANSWER 3 OF 5 USPATFULL

Full-text

ACCESSION NUMBER: 1999:58922 USPATFULL
TITLE: Topical preparation containing a suspension of solid lipid particles
INVENTOR(S): De Vringer, Tom, Zoetermeer, Netherlands
PATENT ASSIGNEE(S): Yamanouchi Europe B.V., Netherlands (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5904932		19990518
APPLICATION INFO.:	US 1995-473121		19950607 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-131480, filed on 4 Oct 1993, now abandoned which is a continuation of Ser. No. US 1992-857467, filed on 25 Mar 1992, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1991-200664	19910325
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Gardner-Lane, Sally	
LEGAL REPRESENTATIVE:	McDonnell Boehnen Hulbert & Berghoff	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	814	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An aqueous suspension of solid lipid nanoparticles, comprising at least one lipid and preferably also at least one emulsifier, for topical application to the body, is provided. The solid lipid nanoparticles have a mean particle size of between 50-1000 nm and their concentration is between 0.01-60 wt %, by weight of the suspension. Also topical preparations, comprising said suspension of solid lipid nanoparticles, are provided. A medicament can be incorporated into the continuous phase of the suspension or in a vehicle, which is added to said suspension.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD higher saturated alcohols, in particular the aliphatic alcohols having 14-30 carbon atoms, such as cetostearyl alcohol;
DETD non-ionic emulsifiers, such as polyoxyethylene sorbitan fatty acid esters (e.g. TWEEN 20®), polyoxyethylene alkyl ethers (e.g. BRIJ 97® and CETOMACROGOL 1000®), polyoxyethylene fatty acid esters (e.g. MYRJ 52®), sorbitan esters (e.g. SPAN 80®), sucrose esters (e.g. WASAG ESTER 7®);
DETD esters, such as isopropyl myristate;
DETD 300 g of solid paraffin, melting point range 54-57° C., was heated at 80° C. 50 g of CETOMACROGOL 1000® (HLB=16.1) was dissolved in 650 ml of water at 80° C. The lipid phase was added to the aqueous. . .
DETD 300 g of solid paraffin, melting point range 54-57° C., was heated at 80° C. 50 g of CETOMACROGOL 1000® was dissolved in 650 ml of water at 80° C. The lipid phase was added to the aqueous phase. . .
DETD 52 g of petrolatum, 72 g of cetostearyl alcohol, 88.8 g of propylene glycol and 0.8 g of methyl-p-hydroxybenzoate (NIPAGIN M®) were heated together at 70° C. 16 g of CETOMACROGOL 1000® were dissolved in 176 g of water at 70° C. Both phases were mixed together, concurrently using a stirrer. . .
DETD 26 g of cetostearyl alcohol heated to 70° C. and 4 g of CETOMACROGOL 1000® dissolved in 50 g of water at 70° C.

Both phases were mixed together, concurrently using a stirrer at. . .

DETD At 30° C. 25 g of isopropylstearate, 54 g of octamethylcyclotetrasiloxane and 6 g of cetyl dimethicone copolymer were mixed using a stirrer at 300 R.P.M. A clear liquid oily mixture was obtained.

DETD 41.2 g of cetostearyl alcohol, 18.5 g of isopropyl myristate and 19.6 g of octamethylcyclotetrasiloxane were heated together at 55° C. 10.3 g of CETOMACROGOL 1000®, 2.4 g of citric acid (1 aq) and 2.3 g of trisodium citrate, were dissolved in 165.6 g of. .

DETD 6 g of cetyl dimethicone copolyol, 30 g of isopropyl myristate and 50 g of octamethylcyclotetrasiloxane were heated together at 30° C. To the dispersion of 1.2., 5 g of NIPAGIN. . .

DETD . . . B® and 10 g of NIPAGIN P® were added. 100 g of the preserved dispersion of 1.2., 6 g of isopropyl myristate, 1.8 g of citric acid (1 aq), 8.2 g of a 10 wt % solution of sodiumhydroxide and a solution. . .

L20 ANSWER 4 OF 5 USPATFULL

Full-text

ACCESSION NUMBER: 1998:54471 USPATFULL

TITLE: Hair care compositions having styling/conditioning agent and plasticizer

INVENTOR(S): Leitch, Steven Hilary, Maineville, OH, United States
Bartz, Lisa Jo, Cincinnati, OH, United States
Fish, Kathleen Brown, Cincinnati, OH, United States

PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5753216		19980519
APPLICATION INFO.:	US 1994-203723		19940228 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-26144, filed on 2 Mar 1993, now abandoned which is a continuation of Ser. No. US 1991-671578, filed on 19 Mar 1991, now abandoned		
DOCUMENT TYPE:	Utility		
PRIMARY EXAMINER:	Venkat, Jyothsan		
LEGAL REPRESENTATIVE:	Lewis, Leonard W., Rosnell, Tara M., Henderson, Loretta J.		
NUMBER OF CLAIMS:	22		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1975		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are hair care compositions containing a hair styling/conditioning copolymer solubilized or dispersed in a volatile silicone fluid, wherein the copolymer-volatile silicone fluid solution further comprises a nonvolatile plasticizer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . carbonate, ethyl palmitate, isooctyl palmitate, methyl ricinoleate, butyl ricinoleate, diisooctyl sebacate, triisobutyl phosphate, isodecyl pelargonate, ethyl valerate, isocetyl alcohol, octododecanol, **isopropyl myristate**, isostearyl alcohol and methyl alkyl silicones having C2 -C20 alkyl and from 1 to about 500 siloxane monomer units.

SUMM . . . No. 4,265,878, Keil, issued May 5, 1981; and U.S. Pat No. 4,421,769, Dixon, et al., issued Dec. 20, 1983. Such **dimethicone** copolyol materials are also disclosed, in hair compositions, in British Patent Application 2,066,659, Abe, published Jul. 15, 1981 (incorporated by reference herein) and Canadian Patent 727,588, Kuehns, issued Feb. 8, 1966 (incorporated by reference herein). Commerically available **dimethicone** polydimethyl-siloxane copolyols which can be used herein, include Silwet Surface Active Copolymers (manufactured by the Union Carbide Corporation); and Dow. . .

SUMM . . . Dodecyl Sulfate/Cetyl Alcohol", 28 J. of Colloid and Interface Science 82-91 (1968); Barry, et al., "The Self-Bodying Action of Alkyltrimethylammonium Bromides/Cetostearyl Alcohol Mixed Emulsifiers; Influence of Quaternary Chain Length", 35 J. of Colloid and Interface Science 689-708 (1971); and Barry, et al., "Rheology of Systems Containing Cetomacrogol 1000-Cetostearyl Alcohol, I. Self Bodying Action", 38 J. of Colloid and Interface Science 616-625 (1972).

SUMM . . . et al., issued May 26, 1981; British Specification 1,532,585, published Nov. 15, 1978; and Fukushima, et al., "The Effect of **Cetostearyl Alcohol** in Cosmetic Emulsions", 98 Cosmetics & Toiletries

89-112 (1983). Fatty esters included among those useful herein are disclosed in. . .

DETD . . . Plus CS Grade D-671

0.70

Glydant 0.37

Perfume 0.02

Water q.s. to 100%

Silicone Gum Premix

G.E. SE 762 0.50

Octamethyl Cyclotetrasiloxane

3.00

Styling Polymer Premix

Styling Polymer3

3.00

Dimethicone copolyol4

Phenyl Pentamethyl Disiloxane

9.00

Hydroxypropyl Pentamethyl Disiloxane

6.00

1 Hydrophobically modified hydroxyethylcellulose available from Aqualon

2 Silicone Gum available from General. . .

CLM What is claimed is:

. . . carbonate, ethyl palmitate, isooctyl palmitate, methyl ricinoleate, butyl ricinoleate, diisooctyl sebacate, triisobutyl phosphate, isodecyl pelargonate, ethyl valerate, isocetyl alcohol, octododecanol, isopropyl myristate, isostearyl alcohol, silicone copolyols, methyl alkyl silicones having C2 -C20 alkyl and from 1 to about 500 siloxane monomer units,. . .

. . . carbonate, ethyl palmitate, isooctyl palmitate, methyl ricinoleate, butyl ricinoleate, diisooctyl sebacate, triisobutyl phosphate, isodecyl pelargonate, ethyl valerate, isocetyl alcohol, octododecanol, isopropyl myristate, isostearyl alcohol, silicone copolyols, methyl alkyl silicones having C2 -C20 alkyl and from 1 to about 500 siloxane monomer units,. . .

L20 ANSWER 5 OF 5 USPATFULL

Full-text

ACCESSION NUMBER: 97:83632 USPATFULL

TITLE: Topical preparation containing a suspension of solid lipid particles

INVENTOR(S): De Vringer, Tom, Zoetermeer, Netherlands

PATENT ASSIGNEE(S): Yamanouchi Europe B.V., Netherlands (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5667800		19970916
APPLICATION INFO.:	US 1995-467212		19950606 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-131480, filed on 4 Oct 1993, now abandoned And a continuation of Ser. No. US 1992-857467, filed on 25 Mar 1992, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1995-91200664	19950325
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Kulkosky, Peter F.	
LEGAL REPRESENTATIVE:	McDonnell Boehnen Hulbert & Berghoff	
NUMBER OF CLAIMS:	3	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	785	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An aqueous suspension of solid lipid nanoparticles, comprising at least one lipid and preferably also at least one emulsifier, for topical application to the body, is provided. The solid lipid nanoparticles have a mean particle size of between 50-1000 nm and their concentration is between 0.01-60 wt %, by weight of the suspension. Also topical preparations, comprising said suspension of solid lipid nanoparticles, are provided. A medicament can be incorporated into the continuous phase of the suspension or in a vehicle, which is added to said suspension.

The invention further provides manufacturing methods for the aqueous

suspension of solid lipid nanoparticles as well as for preparations comprising such suspension.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD higher saturated alcohols, in particular the aliphatic alcohols having 14-30 carbon atoms, such as cetostearyl alcohol;

DETD non-ionic emulsifiers, such as polyoxyethylene sorbitan fatty acid esters (e.g. TWEEN 20®), polyoxyethylene alkyl ethers (e.g. BRIJ 97® and CETOMACROGOL 1000®), polyoxyethylene fatty acid esters (e.g. MYRJ 52®), sorbitan esters (e.g. SPAN 80®), sucrose esters (e.g. WASAG ESTER 7®);

DETD esters, such as isopropyl myristate;

DETD 300 g of solid paraffin, melting point range 54°-57° C., was heated at 80° C. 50 g of CETOMACROGOL 1000® (HLB=16.1) was dissolved in 650 ml of water at 80° C. The lipid phase was added to the aqueous. . . .

DETD 300 g of solid paraffin, melting point range 54°-57° C., was heated at 80° C. 50 g of CETOMACROGOL 1000® was dissolved in 650 ml of water at 80° C. The lipid phase was added to the aqueous phase. . . .

DETD 52 g of petrolatum, 72 g of cetostearyl alcohol, 88.8 g of propylene glycol and 0.8 g of methyl-p-hydroxybenzoate (NIPAGIN M®) were heated together at 70° C. 16 g of CETOMACROGOL 1000® were dissolved in 176 g of water at 70° C. Both phases were mixed together, concurrently using a stirrer. . . .

DETD 26 g of cetostearyl alcohol heated to 70° C. and 4 g of CETOMACROGOL 1000® dissolved in 50 g of water at 70° C. Both phases were mixed together, concurrently using a stirrer at. . . .

DETD At 30° C. 25 g of isopropylstearate, 54 g of octamethylcyclotetrasiloxane and 6 g of cetyl dimethicone copolymer were mixed using a stirrer at 300 R.P.M. A clear liquid oily mixture was obtained.

DETD 41.2 g of cetostearyl alcohol, 18.5 g of isopropyl myristate and 19.6 g of octamethylcyclotetrasiloxane were heated together at 55° C. 10.3 g of CETOMACROGOL 1000®, 2.4 g of citric acid (1 aq) and 2.3 g of trisodium citrate, were dissolved in 165.6 g of. . . .

DETD 6 g of cetyl dimethicone copolyol, 30 g of isopropyl myristate and 50 g of octamethylcyclotetrasiloxane were heated together at 30° C. To the dispersion of 1.2., 5 g of NIPAGIN. . . .

DETD . . . B® and 10 g of NIPAGIN P® were added. 100 g of the preserved dispersion of 1.2., 6 g of isopropyl myristate, 1.8 g of citric acid (1 aq), 8.2 g of a 10 wt % solution of sodiumhydroxide and a solution. . . .

=> index bioscience

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

23.10

89.85

INDEX 'ADISALERTS, ADISINSIGHT, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, ...' ENTERED AT 22:57:00 ON 10 JUL 2001

59 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF.

=> s (11 or fluticasone) and (18 or paraben)

0* FILE ADISALERTS
0* FILE AQUASCI
0* FILE BIOCOMMERCE
0* FILE CABA
0* FILE CAPLUS
0* FILE CEABA-VTB
0* FILE CONFSCI
0* FILE CROPB
0* FILE CROPU

20 FILES SEARCHED...

0* FILE DDFB
0* FILE DDFU

0* FILE DGENE
 0* FILE DRUGB
 0* FILE DRUGU
 0* FILE EMBAL
 0* FILE ESBIODASE
 0* FILE FOMAD
 0* FILE FOREGE
 0* FILE FROSTI
 0* FILE GENBANK
 0* FILE HEALSAFE
 0* FILE IFIPAT
 0* FILE KOSMET
 0* FILE LIFESCI
 0* FILE MEDICONF
 0* FILE NTIS
 0* FILE OCEAN
 0* FILE PASCAL
 0* FILE PHIC
 0* FILE PHIN
 0* FILE SCISEARCH
 21* FILE USPATFULL
 0* FILE WPINDEX

1 FILES HAVE ONE OR MORE ANSWERS, 59 FILES SEARCHED IN STNINDEX

L21 QUE (L1 OR FLUTICASONE) AND (L8 OR PARABEN)

=> d rank

F1 21* USPATFULL

=> s l21

0* FILE ADISALERTS
 0* FILE AQUASCI
 0* FILE BIOCOMMERCE
 0* FILE CABA
 0* FILE CAPLUS

=> s l21

0* FILE ADISALERTS
 0* FILE AQUASCI
 0* FILE BIOCOMMERCE
 0* FILE CABA
 0* FILE CAPLUS

=> fil uspatfull

=> s l21

'CN' IS NOT A VALID FIELD CODE
 0 FLUTICASONE/CN
 207 FLUTICASONE
 0 METHYL PARABEN/CN
 5057 PARABEN
 4142 PARABENS
 8472 PARABEN

(PARABEN OR PARABENS)

L22 21 (L1 OR FLUTICASONE) AND (L8 OR PARABEN)

=> d ibib abs kwic tot

L22 ANSWER 1 OF 21 USPATFULL

Full-text

ACCESSION NUMBER: 2001:90260 USPATFULL
 TITLE: Fatty acid-pharmaceutical agent conjugates
 INVENTOR(S): Webb, Nigel L., Bryn Mawr, PA, United States
 Bradley, Matthews O., Laytonsville, MD, United States
 Swindell, Charles S., Merion, PA, United States
 Shashoua, Victor E., Brookline, MA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001002404	A1	20010531
APPLICATION INFO.:	US 2000-730450	A1	20001205 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-651428, filed on 22 May 1996, ABANDONED		

DOCUMENT TYPE: Utility
LEGAL REPRESENTATIVE: Edward R. Gates, Wolf, Greenfield & Sacks, P.C., 600
Atlantic Avenue, Boston, MA, 02210
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 2511

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of fatty acids and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . Fendosal; Fempipalane; Fentiazac; Flazalone; Fluazacort; Flufenamic Acid; Flumizole; Flunisolid Acetate; Flunixin; Flunixin Meglumine; Fluocortin Butyl; Fluorometholone Acetate; Fluquazone; Flurbiprofen; Fluretofen; Fluticasone Propionate; Furaprofen; Furobufen; Halcinonide; Halobetasol Propionate; Halopredone Acetate; Ibufenac; Ibuprofen; Ibuprofen Aluminum; Ibuprofen Piconol; Ilonidap; Indomethacin; Indomethacin Sodium; Indoprofen; Indoxole; . . .
DETD . . . flosatidil; fluasterone; fluconazole; fludarabine; flumazenil; flumecinol; flumequine; flunarizine; fluocalcitriol; fluorodaunorubicin hydrochloride; fluoxetine, R-; fluoxetine, S-; fluparoxan; flupirtine; flurbiprofen axetil; flurithromycin; fluticasone propionate; flutrimazole; fluvastatin; fluvoxamine; forasartan; forfenimex; formestane; formoterol; formoterol, R,R-; fosfomycin; trometamol; fosinopril; fosphenytoin; fostriecin; fotemustine; gabapentin; gadobenid acid; gadobutrol; . . .
DETD [0297] Suitable preservatives include benzalkonium chloride (0.003-0.03% W/V); chlorobutanol (0.3-0.9% W/V); parabens (0.01-0.25% W/V) and thimerosal (0.004-0.02% W/V).

L22 ANSWER 2 OF 21 USPATFULL

Full-text

ACCESSION NUMBER: 2001:88210 USPATFULL
TITLE: GuanidinyI heterocycle compounds useful as alpha-2 adrenoceptor agonists
INVENTOR(S): Cupps, Thomas Lee, Norwich, NY, United States
Bogdan, Sophie Eva, Maineville, OH, United States
Henry, Raymond Todd, Pleasant Plain, OH, United States
Sheldon, Russell James, Fairfield, OH, United States
Seibel, William Lee, Hamilton, OH, United States
Ares, Jeffrey Joseph, Hamilton, OH, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001000345	A1	20010419
APPLICATION INFO.:	US 2000-727900	A1	20001201 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-308788, filed on 9 Aug 1999, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-32023	19961125 (60)
DOCUMENT TYPE:	Utility	
LEGAL REPRESENTATIVE:	JAMES C. KELLERMAN, THE PROCTER & GAMBLE COMPANY, HEALTH CARE RESEARCH CENTER, 8700 MASON-MONTGOMERY ROAD, MASON, OH, 45040	
NUMBER OF CLAIMS:	44	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2466	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention involves compounds having the following structure:
##STR1##

as described in the Claims; and enantiomers, optical isomers, stereoisomers, diastereomers, tautomers, addition salts, biohydrolyzable amides and esters thereof, as well as pharmaceutical compositions comprising such novel compounds. The invention also relates to the use of such compounds for preventing or treating disorders modulated by alpha-2 adrenoceptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . cellulose, Avicel® RC-591, tragacanth and sodium alginate;

typical wetting agents include lecithin and polysorbate 80; and typical preservatives include methyl paraben and sodium benzoate. Peroral liquid compositions may also contain one or more components such as sweeteners, flavoring agents and colorants. . .

DETD 193. Beclomethasone, preferably at a dosage range of from about 84 to about 336 µg; Fluticasone, preferably at a dosage range of from about 50 to about 400 µg; Budesonide, preferably at a dosage range of. . .

DETD . . . Subject Compound 5 10 mg/ml carrier

Carrier:

Sodium citrate buffer with (percent

Lecithin	0.48%
Carboxymethylcellulose	0.53
Povidone	0.50
Methyl paraben	0.11
Propyl paraben	0.011

DETD . . . Subject Compound 1 10 mg/ml carrier

Carrier:

Sodium citrate buffer with (percent

Lecithin	0.48%
Carboxymethylcellulose	0.53
Povidone	0.50
Methyl paraben	0.11
Propyl paraben	0.011

L22 ANSWER 3 OF 21 USPATFULL

Full-text

ACCESSION NUMBER: 2001:82296 USPATFULL

TITLE: Aqueous compositions containing corticosteroids for nasal and pulmonary delivery

INVENTOR(S): Saidi, Zahir, Philadelphia, PA, United States
Klyashchitsky, Boris, Newark, DE, United States

PATENT ASSIGNEE(S): Elan Corporation plc, Dublin, Israel (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6241969	B1	20010605
APPLICATION INFO.:	US 1998-105838		19980626 (9)
DOCUMENT TYPE:	Utility		
PRIMARY EXAMINER:	Moezie, T.		
LEGAL REPRESENTATIVE:	Synnestvedt & Lechner LLP		
NUMBER OF CLAIMS:	29		
EXEMPLARY CLAIM:	1		
LINE COUNT:	849		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions containing corticosteroid compounds as active agents for the treatment of ailments and diseases of the respiratory tract, particularly the lungs, by way of nasal and pulmonary administration. The corticosteroid compounds are present in a dissolved state in the compositions. The compositions can be formulated in a concentrated, essentially non-aqueous form for storage or in a diluted, aqueous-based form for ready delivery. In a preferred embodiment, the corticosteroid composition contains an ethoxylated derivative of vitamin E and/or a polyethylene glycol fatty acid ester as the high-HLB surfactant present in the formulation. The compositions are ideally suited for inhaled delivery with a nebulizer or for nasal delivery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . budesonide, cloprednol, cortisone, cortivazol, deoxycortone, desonide, desoximetasone, dexamethasone, difluorcortolone, fluclorolone, flumethasone, flunisolide, fluocinolone, fluocinonide, fluocortin butyl, fluorocortisone, fluorocortolone, fluorometholone, flurandrenolone, fluticasone, halcinonide, hydrocortisone, icomethasone, meprednisone, methylprednisolone, mometasone, paramethasone, prednisolone, prednisone, tixocortol, triamcinolone, and others, and their respective pharmaceutically acceptable derivatives, such as beclomethasone dipropionate, dexamethasone 21-isonicotinate, fluticasone propionate, icomethasone enbutate, tixocortol 21-pivalate, triamcinolone acetonide, and others. Fortunately, some of these synthetic steroids have low potentials for systemic. . .

DETD . . . budesonide, cloprednol, cortisone, cortivazol, deoxycortone,

desonide, desoximetasone, dexamethasone, difluorocortolone, fluclorolone, flumethasone, flunisolide, fluocinolone, fluocinonide, fluocortin butyl, fluorocortisone, fluorocortolone, fluorometholone, flurandrenolone, fluticasone, halcinonide, hydrocortisone, icomethasone, meprednisone, methylprednisolone, paramethasone, prednisolone, prednisone, tixocortol, triamcinolone, and their respective pharmaceutically acceptable derivatives, such as beclomethasone dipropionate, dexamethasone 21-isonicotinate, fluticasone propionate, icomethasone enbutate, tixocortol 21-pivalate, and triamcinolone acetonide. Particularly preferred are compounds such as beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate, mometasone and triamcinolone acetonide.

DETD . . . growth in the composition for a storage period of at least six months. Examples of pharmaceutically acceptable preservatives include the parabens, benzalkonium chloride, thimerosal, chlorobutanol, phenylethyl alcohol, benzyl alcohol, and potassium sorbate.

DETD . . . composition is prepared as described above. The corticosteroid for such treatment is preferably either beclomethasone dipropionate, betamethasone, budesonide, dexamethasone, flunisolide, fluticasone propionate, or triamcinolone acetonide, and is formulated in the concentrations set forth above. The daily dose of the corticosteroid is.

CLM What is claimed is:
5. The composition of claim 1 wherein the corticosteroid comprises fluticasone propionate.

L22 ANSWER 4 OF 21 USPATFULL

Full-text

ACCESSION NUMBER: 2001:63708 USPATFULL

TITLE: GuanidinyI heterocycle compounds useful as alpha-2 adrenoceptor agonists

INVENTOR(S): Cupps, Thomas Lee, Norwich, NY, United States
Bogdan, Sophie Eva, Maineville, OH, United States
Henry, Raymond Todd, Pleasant Plain, OH, United States
Sheldon, Russell James, Fairfield, OH, United States
Seibel, William Lee, Hamilton, OH, United States
Ares, Jeffrey Joseph, Hamilton, OH, United States

PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6225331	B1	20010501
	WO 9823596		19980406
APPLICATION INFO.:	US 1999-308788		19990809 (9)
	WO 1997-US20802		19971121
			19990809 PCT 371 date
			19990809 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-32023	19961125 (60)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Seaman, D. Margaret	
LEGAL REPRESENTATIVE:	Kellerman, James C.	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2381	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention involves compounds having the following structure:
##STR1##

as described in the claims; and enantiomers, optical isomers, stereoisomers, diastereomers, tautomers, addition salts, biohydrolyzable amides and esters thereof, as well as pharmaceutical compositions comprising such novel compounds. The invention also relates to the use of such compounds for preventing or treating disorders modulated by alpha-2 adrenoceptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . cellulose, Avicel® RC-591, tragacanth and sodium alginate; typical wetting agents include lecithin and polysorbate 80; and typical preservatives include methyl paraben and sodium benzoate. Peroral liquid compositions may also contain one or more components such as

sweeteners, flavoring agents and colorants. . . .
DETD Beclomethasone, preferably at a dosage range of from about 84 to about
336 µg; Fluticasone, preferably at a dosage range of from about 50
to about 400 µg; Budesonide, preferably at a dosage range of. . .
DETD . . . 10 mg/ml carrier

Carrier:
Sodium citrate buffer with
(percent by weight of carrier):
Lecithin 0.48%
Carboxymethylcellulose 0.53
Povidone 0.50
Methyl paraben 0.11
Propyl paraben 0.011

DETD . . . 10 mg/ml carrier

Carrier:
Sodium citrate buffer with
(percent by weight of carrier):
Lecithin 0.48%
Carboxymethylcellulose 0.53
Povidone 0.50
Methyl paraben 0.11
Propyl paraben 0.011

L22 ANSWER 5 OF 21 USPATFULL

Full-text

ACCESSION NUMBER: 2001:29139 USPATFULL
TITLE: Tocopherol compositions for delivery of biologically
active agents
INVENTOR(S): Sonne, Mette Rydahl, Br.o slashed.ndby Strand, Denmark
PATENT ASSIGNEE(S): A/S Dumex (Dumex Ltd), Copenhagen, Denmark (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6193985	B1	20010227
APPLICATION INFO.:	US 1997-856054		19970514 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-441759, filed on 16 May 1995, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1994-9778	19940516
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Mullis, Jeffrey C.	
LEGAL REPRESENTATIVE:	Watov & Kipnes, P.C., Kipnes, Allen R.	
NUMBER OF CLAIMS:	30	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	958	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides the use of a tocopherol or a derivative
thereof as a solvent and/or emulsifier for substantially insoluble and
sparingly soluble biologically active agents, especially in the
manufacture of pharmaceutical compositions. Such compositions are
particularly suitable for transmucosal, and especially intranasal or
rectal administration, or administration via the oral cavity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM Corticosteroids such as cortisone, hydrocortisone, prednolone,
prednisolone, triamcinolone acetonide, dexamethasone, flunisolide,
budesonide, toxicorole pivalate, betametasone, beclomethasone
dipropionate, fluticasone etc;
SUMM . . . shelf-life it may be desirable to include preservatives such as
benzalkonium chloride, sodium edetate, sorbic acid, potassium sorbate,
phenoxyethanol, phenetanol, parabens or others known in the art.
Addition of odour- or taste-masking compounds can also be desirable.

L22 ANSWER 6 OF 21 USPATFULL

Full-text

ACCESSION NUMBER: 2001:4769 USPATFULL
TITLE: Guanidinylamino heterocycle compounds useful as alpha-2
adrenoceptor agonists
INVENTOR(S): Cupps, Thomas Lee, Norwich, NY, United States
Bogdan, Sophie Eva, Maineville, OH, United States
Henry, Raymond Todd, Pleasant Plain, OH, United States

PATENT ASSIGNEE(S): Sheldon, Russell James, Fairfield, OH, United States
Seibel, William Lee, Hamilton, OH, United States
Ares, Jeffrey Joseph, Hamilton, OH, United States
The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6172095	B1	20010109
	WO 9823591		19980604
APPLICATION INFO.:	US 1999-308790		19990809 (9)
	WO 1997-US20550		19971121
			19990809 PCT 371 date
			19990809 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-31756	19961125 (60)
DOCUMENT TYPE:	Patent	
PRIMARY EXAMINER:	Seaman, D. Margaret	
LEGAL REPRESENTATIVE:	Kellerman, James C., Roof, Carl J.	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2105	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention involves compounds having the structure (I) as described in the claims, and enantiomers, optical isomers, stereoisomers, diastereomers, tautomers, addition salts, biohydrolyzable amides and esters thereof, as well as pharmaceutical compositions comprising such novel compounds. The invention also relates to the use of such compounds for preventing or treating disorders modulated by alpha-2 adrenoceptors.
##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . cellulose, Avicel® RC-591, tragacanth and sodium alginate; typical wetting agents include lecithin and polysorbate 80; and typical preservatives include methyl **paraben** and sodium benzoate. Peroral liquid compositions may also contain one or more components such as sweeteners, flavoring agents and colorants. . . .

DETD Beclomethasone, preferably at a dosage range of from about 84 to about 336 µg; Fluticasone, preferably at a dosage range of from about 50 to about 400 µg; Budesonide, preferably at a dosage range of . . .

DETD . . . 10 mg/ml carrier

Carrier:

Sodium citrate buffer with (percent by weight of carrier):

Lecithin	0.48%
Carboxymethylcellulose	0.53
Povidone	0.50
Methyl paraben	0.11
Propyl paraben	0.011

DETD . . . 10 mg/ml carrier

Carrier:

Sodium citrate buffer with (percent by weight of carrier):

Lecithin	0.48%
Carboxymethylcellulose	0.53
Povidone	0.50
Methyl paraben	0.11
Propyl paraben	0.011

L22 ANSWER 7 OF 21 USPATFULL

Full-text

ACCESSION NUMBER: 2000:171042 USPATFULL

TITLE: 2-imidazolinyllaminoindole compounds useful as alpha-2 adrenoceptor agonists

INVENTOR(S): Henry, Raymond Todd, Pleasant Plain, OH, United States
Sheldon, Russell James, Fairfield, OH, United States
Seibel, William Lee, Hamilton, OH, United States

PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6162818		20001219

APPLICATION INFO.: US 1999-290731 19990413 (9)
 RELATED APPLN. INFO.: Continuation of Ser. No. WO 1997-US20801, filed on 21
 Nov 1997

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-31777	19961111 (60)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	McKane, Joseph K.	
ASSISTANT EXAMINER:	Oswecki, Jane C.	
LEGAL REPRESENTATIVE:	Bott, Cynthia M., Kellerman, James C., Clark, Karen F.	
NUMBER OF CLAIMS:	42	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2524	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention involves compounds having the following structure:
 ##STR1## wherein: a) R1 is hydrogen; or alkyl; bond (a) is a single
 or a double bond;

b) R2 and R3 are each independently selected from hydrogen;
 unsubstituted C1 -C3 alkanyl, alkenyl or alkynyl;
 cycloalkanyl, cycloalkenyl; unsubstituted C1 -C3 alkylthio or
 alkoxy; hydroxy; thio; nitro; cyano; amino; C1 -C3 alkylamino
 or C1 -C3 dialkylamino and halo;

c) R4, R5 and R6 are each independently selected from
 hydrogen; unsubstituted C1 -C3 alkanyl, alkenyl or alkynyl;
 cycloalkanyl, cycloalkenyl; unsubstituted C1 -C3 alkylthio or
 alkoxy; hydroxy; thio; nitro; cyano; amino; C1 -C3 alkylamino
 or C1 -C3 dialkylamino; halo; and 2-imidazolinylamino; and
 wherein one and only one of R4, R5 and R6 is
 2-imidazolinylamino;

d) R7 is selected from hydrogen; unsubstituted C1 -C3
 alkanyl, alkenyl or alkynyl; cycloalkanyl, cycloalkenyl; unsubstituted
 C1 -C3 alkylthio or alkoxy; hydroxy; thio; nitro; cyano;
 amino; C1 -C3 alkylamino or C1 -C3 dialkylamino and
 halo;

e) the compound is not 4-(2-imidazolinylamino)indole;

enantiomers, optical isomers, stereoisomers, diastereomers, tautomers,
 addition salts, biohydrolyzable amides and esters thereof, and
 pharmaceutical compositions comprising such novel compounds. The
 invention also relates to the use of such compounds for treating
 disorders modulated by alpha-2 adrenoceptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . cellulose, Avicel® RC-591, tragacanth and sodium alginate;
 typical wetting agents include lecithin and polysorbate 80; and typical
 preservatives include methyl paraben and sodium benzoate. Peroral
 liquid compositions may also contain one or more components such as
 sweeteners, flavoring agents and colorants. . . .

DETD Steroids, preferably intranasally administered steroids, including:
 Beclomethasone, preferably at a dosage range of from about 84 to about
 336 µg; Fluticasone, preferably at a dosage range of from about 50
 to about 400 µg; Budesonide, preferably at a dosage range of. . . .

DETD . . . Amount per tablet (mg)

Component	Amount
-----------	--------

Subject Compound 5 10 mg/ml carrier

Carrier:

Sodium citrate buffer with (percent
 by weight of carrier):

Lecithin	0.48%
----------	-------

Carboxymethylcellulose	
------------------------	--

	0.53
--	------

Povidone	0.50
----------	------

Methyl paraben	0.11
----------------	------

Propyl paraben	0.011
----------------	-------

DETD

Component	Amount
-----------	--------

Subject Compound I 10 mg/ml carrier

Carrier:
Sodium citrate buffer with (percent
by weight of carrier):
Lecithin 0.48%
Carboxymethylcellulose
0.53
Povidone 0.50
Methyl paraben 0.11
Propyl paraben 0.011

L22 ANSWER 8 OF 21 USPATFULL

Full-text

ACCESSION NUMBER: 2000:121514 USPATFULL
TITLE: 6-(2-imidazolinylamino)quinoxaline compounds useful as
alpha-2 adrenoceptor agonists
INVENTOR(S): Maurer, Peter J., Cincinnati, OH, United States
Henry, Raymond T., Pleasant Plain, OH, United States
Sheldon, Russell James, Fairfield, OH, United States
PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United
States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6117871		20000912
APPLICATION INFO.:	US 1996-755941		19961125 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-496707, filed on 29 Jun 1995, now abandoned which is a continuation-in-part of Ser. No. US 1993-169785, filed on 17 Dec 1993, now abandoned		
DOCUMENT TYPE:	Utility		
PRIMARY EXAMINER:	Fay, Zohreh		
LEGAL REPRESENTATIVE:	Bott, Cynthia M., Kellerman, James C., Suter, David L.		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1432		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The subject invention relates to methods of treating alpha-2
adrenoreceptor modulated disorders, comprising administration, to a
mammal in need of such treatment, of a safe and effective amount of a
compound having the following structure: ##STR1## wherein: (a) R is
unsubstituted C1 -C3 alkanyl or alkenyl; and

(b) R' is selected from hydrogen; unsubstituted C1 -C3 alkanyl
or alkenyl; unsubstituted C1 -C3 alkylthio or alkoxy; hydroxy;
thiol; and halo.

The subject invention also relates compounds and compositions for
preventing or treating of disorders modulated by alpha-2
adrenoreceptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . cellulose, Avicel® RC-591, tragacanth and sodium alginate;
typical wetting agents include lecithin and polysorbate 80; and typical
preservatives include methyl paraben and sodium benzoate. Peroral
liquid compositions may also contain one or more components such as
sweeteners, flavoring agents and colorants. . . .

DETD Beclomethasone, preferably at a dosage range of from about 84 to about
336 µg; Fluticasone, preferably at a dosage range of from about 50
to about 400 µg; Budesonide, preferably at a dosage range of. . . .

DETD . . . 10 mg/ml carrier

Carrier:
Sodium citrate buffer with (percent
by weight of carrier):
Lecithin 0.48%
Carboxymethylcellulose 0.53
Povidone 0.50
Methyl paraben 0.11
Propyl paraben 0.011

DETD . . . 10 mg/ml carrier

Carrier:
Sodium citrate buffer with (percent
by weight of carrier):
Lecithin 0.48%

Carboxymethylcellulose 0.53
Povidone 0.50
Methyl paraben 0.11
Propyl paraben 0.011

L22 ANSWER 9 OF 21 USPATFULL

Full-text

ACCESSION NUMBER: 2000:113979 USPATFULL
TITLE: 2-imidazolinyllaminobenzoxazole compounds useful as
alpha-2 adrenoceptor agonists
INVENTOR(S): Henry, Raymond Todd, Pleasant Plain, OH, United States
Sheldon, Russell James, Fairfield, OH, United States
Seibel, William Lee, Hamilton, OH, United States
PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United
States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6110952		20000829
	WO 9823611		19980604
APPLICATION INFO.:	US 1999-308792		19990809 (9)
	WO 1997-US20803		19971121
			19990809 PCT 371 date
			19990809 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-31787	19961125 (60)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	McKane, Joseph	
ASSISTANT EXAMINER:	Wright, Sonya N	
LEGAL REPRESENTATIVE:	Kellerman, James C., Roof, Carl J.	
NUMBER OF CLAIMS:	42	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1879	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to compounds of formula I, (2-imidazolinyllamino)benzoxazoles. The compounds have been found to be alpha-2 adrenoceptor agonists and are useful for treatment of disorders modulated by alpha-2 adrenoceptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . cellulose, Avicel® RC-591, tragacanth and sodium alginate; typical wetting agents include lecithin and polysorbate 80; and typical preservatives include methyl paraben and sodium benzoate. Peroral liquid compositions may also contain one or more components such as sweeteners, flavoring agents and colorants. . . .

DETD Beclomethasone, preferably at a dosage range of from about 84 to about 336 µg; Fluticasone, preferably at a dosage range of from about 50 to about 400 µg; Budesonide, preferably at a dosage range of. . . .

DETD . . . 10 mg/ml carrier

Carrier:
Sodium citrate buffer with (percent by weight
of carrier):
Lecithin 0.48%
Carboxymethylcellulose 0.53
Povidone 0.50
Methyl paraben 0.11
Propyl paraben 0.011

DETD . . . 10 mg/ml carrier

Carrier:
Sodium citrate buffer with (percent by weight of
carrier):
Lecithin 0.48%
Carboxymethylcellulose 0.53
Povidone 0.50
Methyl paraben 0.11
Propyl paraben 0.011

L22 ANSWER 10 OF 21 USPATFULL

Full-text

ACCESSION NUMBER: 2000:74321 USPATFULL

TITLE: Antifungal/steroid topical compositions
INVENTOR(S): Quigley, Jr., John W., Foster City, CA, United States
Hou, Sui Yuen Eddie, Foster City, CA, United States
Chaudhuri, Bhaskar, Cupertino, CA, United States
PATENT ASSIGNEE(S): Penederm, Inc., Foster City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6075056		20000613
APPLICATION INFO.:	US 1997-943574		19971003 (8)
DOCUMENT TYPE:	Utility		
PRIMARY EXAMINER:	Dees, Jose' G.		
ASSISTANT EXAMINER:	Pryor, Alton		
LEGAL REPRESENTATIVE:	Cooley Godward LLP		
NUMBER OF CLAIMS:	26		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1047		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Stable topical formulations comprising an antifungal agent and an antiinflammatory steroid are disclosed, useful for treating fungal diseases and their related inflammation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . sodium phosphate, and citrates well known in the art. A preservative is generally present, for example benzyl alcohol, sodium benzoate, parabens, and the like.

SUMM Fluticasone propionate ointment, 0.005%

SUMM Fluticasone propionate cream 0.05%

SUMM Sodium benzoate is a preservative and can be replaced by or used in conjunction with benzyl alcohol or parabens, or other commonly used preservatives.

CLM What is claimed is:

. . . chosen from monobasic sodium phosphate and dibasic sodium phosphate, and the preservative is chosen from benzyl alcohol, sodium benzoate and parabens.

L22 ANSWER 11 OF 21 USPATFULL

Full-text

ACCESSION NUMBER: 2000:34393 USPATFULL

TITLE: Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease

INVENTOR(S): Ridker, Paul, Chestnut Hill, MA, United States
Hennekens, Charles H., South Natick, MA, United States

PATENT ASSIGNEE(S): The Brigham and Women's Hospital, Inc., Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6040147		20000321
APPLICATION INFO.:	US 1998-54212		19980402 (9)
DOCUMENT TYPE:	Utility		
PRIMARY EXAMINER:	Saunders, David		
LEGAL REPRESENTATIVE:	Wolf, Greenfield & Sacks, PC		
NUMBER OF CLAIMS:	47		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 5 Drawing Page(s)		
LINE COUNT:	1501		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder by obtaining a level of the marker of systemic inflammation in the individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . Fendosal; Fempipalone; Fentiazac; Flazalone; Fluazacort; Flufenamic Acid; Flumizole; Flunisolide Acetate; Flunixin; Flunixin Meglumine; Fluocortin Butyl; Fluorometholone Acetate; Fluquazone; Flurbiprofen; Fluretofen; Fluticasone Propionate; Furaprofen; Furobufen; Halcinonide; Halobetasol Propionate; Halopredone Acetate;

Ibufenac; Ibuprofen; Ibuprofen Aluminum; Ibuprofen Piconol; Ilonidap;
Indomethacin; Indomethacin Sodium; Indoprofen; Indoxole;. . .
DETD The pharmaceutical compositions also may contain, optionally, suitable
preservatives, such as: benzalkonium chloride; chlorobutanol; parabens
and thimerosal.

L22 ANSWER 12 OF 21 USPATFULL

Full-text

ACCESSION NUMBER: 1999:155755 USPATFULL
TITLE: Peripherally active anti-hyperalgesic opiates
INVENTOR(S): Yaksh, Tony L., San Diego, CA, United States
PATENT ASSIGNEE(S): Regents of the University of California, Oakland, CA,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5994372		19991130
APPLICATION INFO.:	US 1996-712881		19960912 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-528510, filed on 12 Sep 1995, now patented, Pat. No. US 5849761		
DOCUMENT TYPE:	Utility		
PRIMARY EXAMINER:	Spivack, Phyllis G.		
LEGAL REPRESENTATIVE:	Seidman, Stephanie L.Heller Ehrman White & McAuliffe		
NUMBER OF CLAIMS:	29		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 5 Drawing Page(s)		
LINE COUNT:	5274		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods using the compositions for treatment of
peripheral hyperalgesia are provided. The compositions contain an
anti-hyperalgesia effective amount of one or more compounds that
directly or indirectly interact with peripheral opiate receptors, but
that do not, upon topical or local administration, elicit substantial
central nervous system effects. The anti-diarrheal compound
4-(p-chlorophenyl)-4-hydroxy-N-N-dimethyl- α,α -diphenyl-1-
piperidinebutyramide hydrochloride is preferred for use in the
compositions and methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . solution, fixed oil, polyethylene glycol, glycerine, propylene
glycol or other synthetic solvent; antimicrobial agents, such as benzyl
alcohol and alkyl parabens such as methyl parabens; antioxidants,
such as ascorbic acid and sodium bisulfite; chelating agents, such as
ethylenediaminetetraacetic acid [EDTA]; buffers, such as acetates,
citrates. . .

DETD Other ingredients, such as preservatives, including alkyl parabens
such as methyl paraben and ethyl-paraben, perfumes, dyes or the
like, that are known in the art to provide desirable stability,
fragrance or color, or other. . .

DETD Corticosteroids such as Alclometasone, Betamethasone, Clobetasol,
Clocortrolone, Desonide, Desoximetasone, Dexamethasone, Diflorasone,
Fluocinolone, Fluocinonide, Flurandrenolide, Fluticasone,
Floromethalone, Halcinonide, Halobetasol, Hydrocortisone, Loteprednol,
Mometasone, Prednicarbate, Prednisone, and Triamcinolone;

DETD
Weight (%)

(1)

Loperamide hydrochloride 1.75
Propylene glycol 38.5
Methyl paraben 0.30
Tween 20 (Polysorbate) 3.50
Water 29.95

(2)

White petrolatum 18.20
Stearyl alcohol 5.00
Isopropyl myristate 2.50
Liposorb S (sorbitan). . .

DETD A water-washable gel is prepared by adding Transcutol [diethylene glycol
monoethyl ether] to propylene glycol, then dissolving the parabens and
loperamide hydrochloride. Then water and Natrosol are added and mixed
well until the mixture gels.

DETD . . . Weight %

Loperamide hydrochloride

4.00

Propylene glycol 55.00
Transcutol (diethylene glycol monoethyl ether) 5.00
Natrosol 250 HHX (hydroxyethyl cellulose) 2.00
Methyl paraben 0.18
Propyl paraben 0.02
Water 33.80

L22 ANSWER 13 OF 21 USPATFULL

Full-text

ACCESSION NUMBER: 1999:124931 USPATFULL
TITLE: 2-Imidazolinylamino heterocyclic compounds useful as
alpha-2 adrenoceptor agonists
INVENTOR(S): Maurer, Peter J., Cincinnati, OH, United States
Ares, Jeffrey J., Hamilton, OH, United States
Seibel, William L., Hamilton, OH, United States
Walker, Daniel P., Bloomington, IN, United States
Sheldon, Russell James, Fairfield, OH, United States
Henry, Raymond T., Pleasant Plain, OH, United States
PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United
States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5965595		19991012
APPLICATION INFO.:	US 1996-756085		19961125 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-478708, filed on 7 Jun 1995, now patented, Pat. No. US 5663189 which is a continuation-in-part of Ser. No. US 1993-86482, filed on 1 Jul 1993, now abandoned		
DOCUMENT TYPE:	Utility		
PRIMARY EXAMINER:	Goldberg, Jerome D.		
LEGAL REPRESENTATIVE:	Kellerman, James C., Roof, Carl J., Suter, David L.		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	2		
LINE COUNT:	1891		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The subject invention relates to compounds having the structure:
##STR1## wherein (a) n is an integer from 1 to about 3;

(b) X and Y are each independently selected from O, S and CH₂, with
at least one of X and Y being O or S;

(c) R is unsubstituted, straight or branched chain alkanyl or alkanoxy
having from 1 to about 3 non-hydrogen atoms; and

(d) R' is selected from hydrogen, methyl, cyano, and halo;

pharmaceutical compositions containing such compounds; and the use of
such compounds for preventing or treating of disorders modulated by
alpha-2 adrenoceptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . cellulose, Avicel® RC-591, tragacanth and sodium alginate;
typical wetting agents include lecithin and polysorbate 80; and typical
preservatives include methyl paraben and sodium benzoate. Peroral
liquid compositions may also contain one or more components such as
sweeteners, flavoring agents and colorants. . . .
DETD Beclomethasone, preferably at a dosage range of from about 84 to about
336 µg; Fluticasone, preferably at a dosage range of from about 50
to about 400 µg; Budesonide, preferably at a dosage range of . . .
DETD . . . Amount per tablet (mg)

Component	Amount
Subject Compound 5	10 mg/ml carrier
Carrier:	
Sodium citrate buffer with (percent by weight of carrier):	
Lecithin	0.48%
Carboxymethylcellulose	0.53
Povidone	0.50
Methyl paraben	0.11

Propyl paraben 0.011

DETD

Component Amount

Subject Compound I

10 mg/ml carrier

Carrier:

Sodium citrate buffer with (percent
by weight of carrier):

Lecithin 0.48%

Carboxymethylcellulose

0.53

Povidone 0.50

Methyl paraben 0.11

Propyl paraben 0.011

L22 ANSWER 14 OF 21 USPATFULL

Full-text

ACCESSION NUMBER: 1999:72592 USPATFULL

TITLE: 7-(2-imidazolinyllamino)quinoline compounds useful as
alpha-2 adrenoceptor agonists

INVENTOR(S): Cupps, Thomas Lee, Oxford, OH, United States
Bogdan, Sophie E., Maineville, OH, United States
Henry, Raymond T., Pleasant Plain, OH, United States
Sheldon, Russell James, Fairfield, OH, United States
PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United
States (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 5916900 19990629
APPLICATION INFO.: US 1996-758118 19961125 (8)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-496796, filed
on 29 Jun 1995, now patented, Pat. No. US 5716966
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Fay, Zohreh
LEGAL REPRESENTATIVE: Kellerman, James C., Graff, Milton B., Suter, David L.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 1627

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention involves the use of compounds having the
following structure: ##STR1## wherein: (a) R is unsubstituted C1
-C3 alkanyl or alkenyl; and

(b) R' is selected from hydrogen; unsubstituted C1 -C3 alkanyl
or alkenyl; unsubstituted C1 -C3 alkylthio or alkoxy; hydroxy;
thiol; cyano; and halo;

for preventing or treating of disorders modulated by alpha-2
adrenoceptors.

The subject invention also involves novel compounds and compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . cellulose, Avicel® RC-591, tragacanth and sodium alginate;
typical wetting agents include lecithin and polysorbate 80; and typical
preservatives include methyl paraben and sodium benzoate. Peroral
liquid compositions may also contain one or more components such as
sweeteners, flavoring agents and colorants. . . .

DETD Beclomethasone, preferably at a dosage range of from about 84 to about
336 µg; Fluticasone, preferably at a dosage range of from about 50
to about 400 µg; Budesonide, preferably at a dosage range of. . . .

DETD . . . Amount per tablet (mg)

Component Amount

Subject Compound 1 10 mg/ml carrier

Carrier:

Sodium citrate buffer with (percent
by weight of carrier):

Lecithin 0.48%

Carboxymethylcellulose

0.53

Povidone 0.50
Methyl paraben 0.11
Propyl paraben 0.011
For the reduction of cardiac reperfusion injury.

DETD

Component	Amount
Subject Compound I	10 mg/ml carrier
Carrier:	
Sodium citrate buffer with (percent by weight of carrier):	
Lecithin	0.45%
Carboxymethylcellulose	0.53
Povidone	0.50
Methyl paraben	0.11
Propyl paraben	0.011

L22 ANSWER 15 OF 21 USPATFULL

Full-text

ACCESSION NUMBER: 1999:69731 USPATFULL
TITLE: 2-imidazolinyllamino heterocyclic compounds useful as alpha-2 adrenoceptor agonists
INVENTOR(S): Maurer, Peter J., Cincinnati, OH, United States
Ares, Jeffrey J., Hamilton, OH, United States
Seibel, William L., Hamilton, OH, United States
Walker, Daniel P., Bloomington, OH, United States
Sheldon, Russell James, Fairfield, OH, United States
Henry, Raymond T., Pleasant Plain, OH, United States
PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5914342		19990622
APPLICATION INFO.:	US 1998-159698		19980924 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-756085, filed on 25 Nov 1996 which is a continuation-in-part of Ser. No. US 1995-478708, filed on 7 Jun 1995, now patented, Pat. No. US 5663189		
DOCUMENT TYPE:	Utility		
PRIMARY EXAMINER:	Goldberg, Jerome D.		
LEGAL REPRESENTATIVE:	Kellerman, James C., Roof, Carl J., Graff, Milton B.		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1872		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The subject invention relates to compounds having the structure:
##STR1## wherein (a) n is an integer from 1 to about 3;

(b) X and Y are each independently selected from O, S and CH₂, with at least one of X and Y being O or S;

(c) R is unsubstituted, straight or branched chain alkanyl or alkanoxy having from 1 to about 3 non-hydrogen atoms; and

(d) R' is selected from hydrogen, methyl, cyano, and halo;
pharmaceutical compositions containing such compounds; and the use of such compounds for preventing or treating of disorders modulated by alpha-2 adrenoceptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . cellulose, Avicel® RC-591, tragacanth and sodium alginate; typical wetting agents include lecithin and polysorbate 80; and typical preservatives include methyl paraben and sodium benzoate. Peroral liquid compositions may also contain one or more components such as sweeteners, flavoring agents and colorants. . . .
DETD Beclomethasone, preferably at a dosage range of from about 84 to about 336 µg; Fluticasone, preferably at a dosage range of from about 50 to about 400 µg; Budesonide, preferably at a dosage range of. . . .
DETD . . . Amount per tablet (mg)
Component Amount

Subject Compound 5 10 mg/ml carrier
 Carrier:
 Sodium citrate buffer with (percent
 by weight of carrier):
 Lecithin 0.48%
 Carboxymethylcellulose
 0.53
 Povidone 0.50
 Methyl paraben 0.11
 Propyl paraben 0.011

Component	Amount
Subject Compound I	10 mg/ml carrier
Carrier:	
Sodium citrate buffer with (percent by weight of carrier):	
Lecithin	0.48%
Carboxymethylcellulose	0.53
Povidone	0.50
Methyl paraben	0.11
Propyl paraben	0.011

L22 ANSWER 16 OF 21 USPATFULL

Full-text

ACCESSION NUMBER: 1998:108418 USPATFULL
 TITLE: 6-(2-imidazolinyllamino) quinolines useful as alpha-2
 adrenoceptor agonists
 INVENTOR(S): Cupps, Thomas Lee, Oxford, OH, United States
 Maurer, Peter J., Cincinnati, OH, United States
 Ares, Jeffrey J., Hamilton, OH, United States
 Henry, Raymond T., Pleasant Plain, OH, United States
 Sheldon, Russell James, Fairfield, OH, United States
 Mieling, Glen E., West Chester, OH, United States
 Bogdan, Sophie E., Maineville, OH, United States
 PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United
 States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5804587		19980908
APPLICATION INFO.:	US 1996-755936		19961125 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-496704, filed on 29 Jun 1995, now patented, Pat. No. US 5739148		
DOCUMENT TYPE:	Utility		
PRIMARY EXAMINER:	Ramsuer, Robert W.		
ASSISTANT EXAMINER:	Sackey, Ebenezer O.		
LEGAL REPRESENTATIVE:	Hake, Richard A., Graff, Milton B., Suter, David L.		
NUMBER OF CLAIMS:	36		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1924		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The subject invention relates to compounds having the structure:
 ##STR1## as defined in the claims, and to pharmaceutical compositions
 containing such compounds, and the use of such compounds for preventing
 or treating of disorders modulated by alpha-2 adrenoceptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . cellulose, Avicel® RC-591, tragacanth and sodium alginate;
 typical wetting agents include lecithin and polysorbate 80; and typical
 preservatives include methyl paraben and sodium benzoate. Peroral
 liquid compositions may also contain one or more components such as
 sweeteners, flavoring agents and colorants. . . .
 DETD Steroids, Preferably intranasally administered steroids, including:
 Beclomethasone, preferably at a dosage range of from about 84 to about
 336 µg; Fluticasone, preferably at a dosage range of from about 50
 to about 400 µg; Budesonide, preferably at a dosage range of. . . .
 DETD . . . Amount per tablet (mg)
 Component Amount

Subject Compound 5 10 mg/ml carrier
 Carrier:

Sodium citrate buffer with
(percent by weight of carrier):
Lecithin 0.48%
Carboxymethylcellulose
0.53
Povidone 0.50
Methyl paraben 0.11
Propyl paraben 0.011

DETD

Component	Amount
-----------	--------

Subject Compound I	10 mg/ml carrier
--------------------	------------------

Carrier:

Sodium citrate buffer with
(percent by weight of carrier):
Lecithin 0.48%
Carboxymethylcellulose
0.53
Povidone 0.50
Methyl paraben 0.11
Propyl paraben 0.011

L22 ANSWER 17 OF 21 USPATFULL

Full-text

ACCESSION NUMBER: 1998:98932 USPATFULL

TITLE: DHA-pharmaceutical agent conjugates of taxanes

INVENTOR(S): Shashoua, Victor E., Brookline, MA, United States
Swindell, Charles S., Merion, PA, United States
Webb, Nigel L., Bryn Mawr, PA, United States
Bradley, Matthews O., Laytonsville, MD, United States
PATENT ASSIGNEE(S): Neuromedica, Inc., Conshohocken, PA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5795909		19980818
APPLICATION INFO.:	US 1996-651312		19960522 (8)
DOCUMENT TYPE:	Utility		
PRIMARY EXAMINER:	Jarvis, William R. A.		
LEGAL REPRESENTATIVE:	Wolf, Greenfield & Sacks, P.C.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	27 Drawing Figure(s); 14 Drawing Page(s)		
LINE COUNT:	2451		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of cis-docosahexaenoic acid and taxanes useful in treating cell proliferative disorders. Conjugates of paclitaxel and docetaxel are preferred.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . Fendosal; Fempipalane; Fentiazac; Flazalone; Fluazacort;
Flufenamic Acid; Flumizole; Flunisolid Acetate; Flunixin; Flunixin
Meglumine; Fluocortin Butyl; Fluorometholone Acetate; Fluquazone;
Flurbiprofen; Fluretofen; Fluticasone Propionate; Furaprofen;
Furobufen; Halcinonide; Halobetasol Propionate; Halopredone Acetate;
Ibufenac; Ibuprofen; Ibuprofen Aluminum; Ibuprofen Piconol; Ilonidap;
Indomethacin; Indomethacin Sodium; Indoprofen; Indoxole;. . .
DETD . . . flosatidil; fluasterone; fluconazole; fludarabine; flumazenil;
flumecinol; flumequine; flunarizine; fluocalcitriol; fluorodaunorubicin
hydrochloride; fluoxetine, R-; fluoxetine, S-; fluparoxan; flupirtine;
flurbiprofen axetil; flurithromycin; fluticasone propionate;
flutrimazole; fluvastatin; fluvoxamine; forasartan; forfenimex;
formestane; formoterol; formoterol, R,R-; fosfomycin; trometamol;
fosinopril; fosphenytoin; fostriecin; fotemustine; gabapentin; gadobenil
acid; gadobutrol;. . .
DETD Suitable preservatives include benzalkonium chloride (0.003-0.03% W/V);
chlorobutanol (0.3-0.9% W/V); parabens (0.01-0.25% W/V) and thimerosal
(0.004-0.02% W/V).

L22 ANSWER 18 OF 21 USPATFULL

Full-text

ACCESSION NUMBER: 1998:19697 USPATFULL

TITLE: Rectal flunisolid compositions for treating

INVENTOR(S): inflammatory intestinal disorders
Bernareggi, Virgilio, Cologno Monzese, Italy
Fano, Maurizio, Bresso, Italy
Gagnoni, Alessandro, Milan, Italy
PATENT ASSIGNEE(S): Valeas S.p.A. Industria Chimica E Farmaceutica, Milan,
Italy (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5721228		19980224
	WO 9412187		19940609
APPLICATION INFO.:	US 1995-436291		19950517 (8)
	WO 1993-EP3228		19931118
			19950517 PCT 371 date
			19950517 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	IT 1992-MI2657	19921120
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Henley, III, Raymond	
LEGAL REPRESENTATIVE:	Kenyon & Kenyon	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
LINE COUNT:	382	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Topical rectal therapeutic composition containing, as the active ingredient, flunisolide and/or one or more ester derivatives of same, in combination with suitable excipients and/or diluents, for the treatment of inflammatory intestinal disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . be attributable to its rapid metabolic inactivation in the liver. Nevertheless it gives no indication of the absorption levels of fluticasone and its noxious effects, and there is no suggestion that it would be of use in treating inflammatory intestinal disorders.

SUMM . . . 0-5 to 10 mg each, more preferably from 1 to 5 mg each, and generally containing preservatives, preferably selected among Parabens, chelating agents, such as for example ethylenediaminetetraacetic acid or the relative sodium salt. Should said enemas be emulsions or suspensions, . . .

SUMM preservatives, such as Parabens--also used for enemas;

L22 ANSWER 19 OF 21 USPATFULL

Full-text

ACCESSION NUMBER: 1998:14813 USPATFULL
TITLE: 7-(2-imidazolinyllamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
INVENTOR(S): Cupps, Thomas Lee, Oxford, OH, United States
Bogdan, Sophie Eva, Mainville, OH, United States
PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5716966		19980210
APPLICATION INFO.:	US 1995-496796		19950629 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-292672, filed on 18 Aug 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-169342, filed on 17 Dec 1993, now abandoned		
DOCUMENT TYPE:	Utility		
PRIMARY EXAMINER:	Fay, Zohreh		
LEGAL REPRESENTATIVE:	Hake, Richard A., Graff, Milton B.		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1251		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The subject invention involves methods of treating nasal congestion comprising administration, to a human or lower animal in need of such treatment of a safe and effective amount of a compound having the following structure: ##STR1## wherein: (a) R is unsubstituted C1 -C3 alkanyl or alkenyl; and

(b) R' is selected from hydrogen; unsubstituted C1 -C3 alkanyl

or alkenyl; unsubstituted C1 -C3 alkylthio or alkoxy; hydroxy; thiol; cyano; and halo.

The subject invention also involves the use of such compounds for preventing or treating other respiratory, ocular and/or gastrointestinal disorders. The subject invention also involves novel compounds having the above structure wherein R' is hydrogen or fluoro or cyano.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . cellulose, Avicel® RC-591, tragacanth and sodium alginate; typical wetting agents include lecithin and polysorbate 80; and typical preservatives include methyl paraben and sodium benzoate. Peroral liquid compositions may also contain one or more components such as sweeteners, flavoring agents and colorants. . . .

DETD Beclomethasone, preferably at a dosage range of from about 84 to about 336 ug; Fluticasone, preferably at a dosage range of from about 50 to about 400 ug; Budesonide, preferably at a dosage range of. . .

DETD

Ingredient Amount/15 mL Dose

Subject Compound 4	30	mg
Sucrose	8.16	g
Glycerin	300	mg
Sorbitol	300	mg
Methyl paraben	19.5	mg
Propylparaben	4.5	mg
Menthol	22.5	mg
Eucalyptus oil	7.5	mg
Flavorants	0.07	mL
FD & C Red #40 dye	3.0	mg
Sodium saccharin	30.	

L22 ANSWER 20 OF 21 USPATFULL

Full-text

ACCESSION NUMBER: 97:109926 USPATFULL

TITLE: 5-(2-imidazolinylamino)benzimidazole compounds useful as alpha-2-adrenoceptor agonists

INVENTOR(S): Cupps, Thomas Lee, Oxford, OH, United States
Bogdan, Sophie Eva, Maineville, OH, United States

PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 5691370 19971125

APPLICATION INFO.: US 1996-675745 19960703 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-496706, filed on 29 Jun 1995, now patented, Pat. No. US 5541210 which is a continuation-in-part of Ser. No. US 1994-349558, filed on 8 Dec 1994, now patented, Pat. No. US 5478858 which is a continuation-in-part of Ser. No. US 1993-169868, filed on 17 Dec 1993, now abandoned

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Jordan, Kimberly

LEGAL REPRESENTATIVE: Hake, Richard A., Graff, IV, Milton B., Suter, David L.

NUMBER OF CLAIMS: 2

EXEMPLARY CLAIM: 1

LINE COUNT: 1219

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The subject invention involves compounds having the following structure:
##STR1## wherein: (a) R is unsubstituted C1 -C3 alkanyl or alkenyl;

(b) R' is selected from hydrogen; unsubstituted C1 -C3 alkanyl or alkenyl; unsubstituted C1 -C3 alkylthio or alkoxy; hydroxy; thiol; cyano; and halo; and

(c) R" is selected from hydrogen, methyl, ethyl and i-propyl.

The subject invention also involves pharmaceutical compositions containing such novel compounds, compositions thereof and the use of such compounds for preventing or treating respiratory, ocular and/or gastrointestinal disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.